Design Therapeutics financials
$12.62+2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$22.2M | -$19.7M | -$18.2M | -$19.3M | -$21.6M | -$20.4M | -$16.7M | -$16.2M | -$15.0M | -$14.4M | -$15.1M | -$18.8M |
| Net income | -$20.2M | -$17.6M | -$16.0M | -$17.0M | -$19.1M | -$17.7M | -$13.7M | -$13.0M | -$11.8M | -$11.1M | -$11.8M | -$15.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.32 | $-0.29 | $-0.27 | $-0.30 | $-0.34 | $-0.31 | $-0.24 | $-0.23 | $-0.21 | $-0.20 | $-0.21 | $-0.28 |
| EBITDA | -$22.0M | -$19.5M | -$18.0M | -$19.2M | -$21.4M | -$20.3M | -$16.5M | -$16.1M | -$14.9M | -$14.3M | -$15.0M | -$18.7M |
| Operating cash flow | -$15.5M | -$16.4M | -$12.0M | -$11.2M | -$14.4M | -$16.8M | -$9.9M | -$9.5M | -$11.3M | -$12.4M | -$12.8M | -$14.5M |
| Free cash flow | -$15.5M | -$16.4M | -$12.0M | -$11.2M | -$14.5M | -$16.9M | -$9.9M | -$9.6M | -$11.4M | -$12.6M | -$12.8M | -$14.6M |
| Diluted shares | 62.5M | 61.4M | 58.8M | 57.0M | 56.9M | 56.8M | 56.7M | 56.6M | 56.6M | 56.5M | 56.1M | 56.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.9M | $12.8M | $16.9M | $15.1M | $19.7M | $13.7M |
| Short-term investments | $194.5M | $210.1M | $203.0M | $190.9M | $196.6M | $216.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $215.1M | $230.4M | $226.2M | $211.8M | $222.9M | $237.5M |
| Total liabilities | $13.3M | $12.4M | $13.7M | $12.1M | $9.8M | $9.6M |
| Shareholders' equity | $201.9M | $218.1M | $212.5M | $199.7M | $213.0M | $227.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology